MedPath

Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)

Phase 2
Completed
Conditions
Cardiovascular Disease
Chronic Kidney Disease
Death
Interventions
Drug: High Dose Multivitamin
Device: Low Dose Multivitamin
Registration Number
NCT00064753
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Brief Summary

The purpose of this randomized clinical trial is to determine if lowering homocysteine levels in renal transplant recipients with a multivitamin will reduce the occurrence of cardiovascular disease outcomes.

Detailed Description

The hypothesis of the trial is as follows: Treatment with a high dose combination of folic acid, vitamin B6, and vitamin B12 will reduce the rate of pooled arteriosclerotic cardiovascular disease outcomes (i.e., pooled occurrence of non-fatal and fatal arteriosclerotic outcomes, including coronary heart, cerebrovascular, and peripheral vascular disease events) relative to treatment with an identical multivitamin containing no folic acid, and Estimated Average Requirement amounts of vitamin B6, vitamin B12, among chronic, stable renal transplant recipients

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
4110
Inclusion Criteria
  • 35 - 75 years old
  • Had kidney transplant at least 6 months
  • Calculated Creatinine Clearance must be 25 mL/min or greater
  • Must be willing to stop supplements (B6, B12, folic acid) for 4-6 weeks prior to visit
Exclusion Criteria
  • If pregnant or lactating

  • If of child bearing potential and not on birth control

  • If any of the following will limit life expectancy to less than 2 yrs:

    • Cancer
    • Congestive heart failure (CHF) (end stage)
    • Liver disease (end stage)
    • Severe pulmonary disease
    • Progressive HIV
    • Any other chronic wasting illness
  • If patient had myocardial infarction (MI), stroke, lower extremity amputation above ankle or percutaneous revascularization procedure (coronary, cerebrovascular, lower extremity) in past 2months

  • If patient had coronary artery bypass graft (CABG) or abdominal aortic aneurysm (AAA) in past 5 months

  • If patient has conditions that prevent reliable study participation e.g., depression, alcohol or drug abuse, other cardiovascular disease (CVD) studies

  • If patient has had multi-organ transplant, except kidney/pancreas

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
High Dose MultivitaminHigh Dose MultivitaminMultivitamin with increased folic acid, vitamin B6 and vitamin B12
Low Dose MultivitaminLow Dose MultivitaminMultivitamin devoid of folic acid and with estimated average requirement amounts of vitamin B6 and vitamin B12
Primary Outcome Measures
NameTimeMethod
Recurrent or de Novo Arteriosclerotic Cardiovascular Disease (CVD) Defined as the Occurrence of Non-fatal or Fatal Arteriosclerotic Outcomes Including Coronary Heart, Cerebrovascular, and Peripheral Vascular Disease EventsUp to 6 years (mean 4 years)
Secondary Outcome Measures
NameTimeMethod
Fatal/Non-fatal Myocardial Infarction (MI)Up to 6 years (mean 4 years)

censored at 3 months after return to dialysis

CVD DeathUp to 6 years (mean 4 years)

censored at 3 months after return to dialysis

Coronary Artery RevascularizationUp to 6 years (mean 4 years)

censored at 3 months after return to dialysis

Resuscitated Sudden Death (RSD)Up to 6 years (mean 4 years)

censored at 3 months after return to dialysis

Mortality (All-cause)Up to 6 years (mean 4 years)

censored at 3 months after return to dialysis

Fatal/Non-fatal StrokeUp to 6 years (mean 4 years)

censored at 3 months after return to dialysis

Renal Graft FailureUp to 6 years (mean 4 years)
Lower Extremity Peripheral Arterial Disease (PAD)Up to 6 years (mean 4 years)

censored at 3 months after return to dialysis

Carotid Endarterectomy or AngioplastyUp to 6 years (mean 4 years)

censored at 3 months after return to dialysis

Abdominal Aortic Aneurysm RepairUp to 6 years (mean 4 years)

censored at 3 months after return to dialysis

Renal Artery RevascularizationUp to 6 years (mean 4 years)

censored at 3 months after return to dialysis

Trial Locations

Locations (30)

Medical College of Wisconsin

🇺🇸

Milwaukee, Wisconsin, United States

Cedars-Sinai Health System/Center for Kidney Diseases and Transplantation

🇺🇸

Los Angeles, California, United States

University of California at Los Angeles

🇺🇸

Los Angeles, California, United States

Northwestern University

🇺🇸

Chicago, Illinois, United States

University of Maryland Medical Center

🇺🇸

Baltimore, Maryland, United States

Toronto General Hospital

🇨🇦

Toronto, Ontario, Canada

Indiana University

🇺🇸

Indianapolis, Indiana, United States

State University of New York Downstate Medical Center

🇺🇸

Brooklyn, New York, United States

University of California at San Francisco

🇺🇸

San Francisco, California, United States

Banner Good Samaritan Transplant

🇺🇸

Phoenix, Arizona, United States

University of Alabama at Birmingham School of Medicine

🇺🇸

Birmingham, Alabama, United States

Southern Illinois University

🇺🇸

Springfield, Illinois, United States

University of Iowa Hospitals and Clinics

🇺🇸

Iowa City, Iowa, United States

Maine Medical Center

🇺🇸

Portland, Maine, United States

Albany Medical Center

🇺🇸

Albany, New York, United States

Brigham and Women's Hospital

🇺🇸

Boston, Massachusetts, United States

University of Michigan Medical Center

🇺🇸

Ann Arbor, Michigan, United States

Faireview University Medical Center

🇺🇸

Minneapolis, Minnesota, United States

Mayo Clinic

🇺🇸

Rochester, Minnesota, United States

Duke University Medical Center

🇺🇸

Durham, North Carolina, United States

University of Wisconsin at Madison

🇺🇸

Madison, Wisconsin, United States

Universidade Federal de Sao Paulo

🇧🇷

Sao Paulo, SP, Brazil

Hennepin County Medical Center

🇺🇸

Minneapolis, Minnesota, United States

London Health Sciences Center

🇨🇦

London, Ontario, Canada

The Ohio State University Medical Center

🇺🇸

Columbus, Ohio, United States

Washington University

🇺🇸

Saint Louis, Missouri, United States

East Carolina University

🇺🇸

Greenville, North Carolina, United States

Drexel University

🇺🇸

Philadelphia, Pennsylvania, United States

Oregon Health Sciences University

🇺🇸

Portland, Oregon, United States

Rhode Island Hospital

🇺🇸

Providence, Rhode Island, United States

© Copyright 2025. All Rights Reserved by MedPath